<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1582</article-id><article-id pub-id-type="doi">10.15690/vramn1582</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>INFECTIOUS DISEASES: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ИНФЕКЦИОННЫХ БОЛЕЗНЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A Prospective Multicenter Randomized Study State of Humoral Immunity after a New Coronavirus Infection (COVID-19) of a Mild or Asymptomatic Course</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности формирования и продолжительность сохранения нейтрализующих антител к S-белку SARS-CoV-2 у лиц, перенесших новую коронавирусную инфекцию (COVID-19) легкого или бессимптомного течения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8396-1936</contrib-id><contrib-id contrib-id-type="spin">3900-3441</contrib-id><name-alternatives><name xml:lang="en"><surname>Kryukov</surname><given-names>Evgeniy V.</given-names></name><name xml:lang="ru"><surname>Крюков</surname><given-names>Евгений Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Corresponding Member of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН</p></bio><email>evgeniy.md@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="spin">1082-0719</contrib-id><name-alternatives><name xml:lang="en"><surname>Trishkin</surname><given-names>Dmitriy V.</given-names></name><name xml:lang="ru"><surname>Тришкин</surname><given-names>Дмитрий Вячеславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>vmeda-nio@mil.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1851-0941</contrib-id><contrib-id contrib-id-type="spin">4531-6011</contrib-id><name-alternatives><name xml:lang="en"><surname>Salukhov</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>Салухов</surname><given-names>Владимир Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д.м.н., доцент</p></bio><email>vlasaluk@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6022-5709</contrib-id><contrib-id contrib-id-type="spin">1542-2836</contrib-id><name-alternatives><name xml:lang="en"><surname>Sadovnikov</surname><given-names>Pavel S.</given-names></name><name xml:lang="ru"><surname>Садовников</surname><given-names>Павел Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>sadovnikov.p@helix.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2016-8815</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreychuk</surname><given-names>Yuriy V.</given-names></name><name xml:lang="ru"><surname>Андрейчук</surname><given-names>Юрий Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>andreychuk.y@helix.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2532-6133</contrib-id><contrib-id contrib-id-type="spin">3839-7619</contrib-id><name-alternatives><name xml:lang="en"><surname>Chugunov</surname><given-names>Alexander A.</given-names></name><name xml:lang="ru"><surname>Чугунов</surname><given-names>Александр Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Adjunct</p></bio><bio xml:lang="ru"><p>адъюнкт</p></bio><email>alexandrchugun@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7537-1218</contrib-id><contrib-id contrib-id-type="spin">4038-0855</contrib-id><name-alternatives><name xml:lang="en"><surname>Kotiv</surname><given-names>Bogdan N.</given-names></name><name xml:lang="ru"><surname>Котив</surname><given-names>Богдан Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>kotivbn@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Military Medical Academy named after S.M. Kirov</institution></aff><aff><institution xml:lang="ru">Военно-медицинская академия им. С.М. Кирова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Main Military Medical Directorate</institution></aff><aff><institution xml:lang="ru">Главное Военно-медицинское управление</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Laboratory Service “Helix”</institution></aff><aff><institution xml:lang="ru">Лабораторная служба «Хеликс»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-10-22" publication-format="electronic"><day>22</day><month>10</month><year>2021</year></pub-date><volume>76</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>361</fpage><lpage>367</lpage><history><date date-type="received" iso-8601-date="2021-05-30"><day>30</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-09"><day>09</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Издательство "Педиатръ"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2022-10-22"/></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/1582">https://vestnikramn.spr-journal.ru/jour/article/view/1582</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>The rapid spread of COVID-19 in the world, the severity of disease, high morbidity and mortality have rightly made the COVID-19 pandemic a major threat to humanity. Therefore, one of the most urgent problems for practical health care is the issue of development of immunity for COVID-19 survivors, the possibility of re-infection, and the appropriateness of vaccination. The article presents the interim results of the study was named “RESPONSE” devoted to assessing the immunity for 90 days from patients that survived COVID-19 in a mild or asymptomatic course. </p> <p><bold>Aims</bold> — to study of the dynamics of generation of SARS-CoV-2 adhesive (S) protein neutralizing antibodies (IgG) and specificities of humoral immunity from COVID-19 survivors with light and asymptomatic form of disease in depending on gender and age. </p> <p><bold>Materials and methods.</bold> Joint study by the Military Medical Academy n.a. S.M. Kirov and Laboratory Service “Helix” is being undertaken in the period from January 06, 2020 to August 1, 2021 on the basis of Academy clinics and Helix diagnostic centers in Saint Petersburg. The study was included 1109 males and females aged 18 to 70 (average age 38.2), who received to outpatient treatment of light and asymptomatic form of New Coronavirus Infection. All patients included in the investigation were done survey of quantitative neutralizing antibodies of class IgG to S-protein SARS-CoV-2 content in venous blood in 30, 45, 60 and 90 days from the last result of positive polymerase chain reaction with reverse transcription (OT-PCR) for determining nucleic acid SARS-CoV-2 in biological material by immunochemiluminescent analysis (LIAISON XL, DiaSorin S.p.A., made in Italy).<bold> </bold></p> <p><bold>Results.</bold> The IgG class antibody to the S-protein SARS-CoV-2 were not diagnosed 30 days after the survived infection only 0.9% of young women (18–44 years) and 0.8% of men in the same age bracket. In other age groups, antibodies were defined in all participants of study. Titer of IgG gradually increases to peak concentration after 45 days, it’s kept at this level to the 60th day, and then it has a decreasing trend after 90 days from the onset of the disease. </p> <p><bold>Conclusions. </bold>The results show the timing of generation and duration of the humoral response in survived patients COVID-19 in a mild or asymptomatic form. For 45 days, antibodies were determined in all participants of the study, reflecting the development of post-infectious humoral immunity, which was maintained in patients with the mild or asymptomatic forms of COVID-19 at least 3 months.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Стремительное распространение новой коронавирусной инфекции (COVID-19) в мире, тяжесть течения, высокая заболеваемость и смертность по праву внесли пандемию COVID-19 в число серьезных угроз для человечества. Поэтому одной из актуальных проблем для практического здравоохранения является вопрос формирования иммунитета у лиц, перенесших COVID-19, возможность их повторного заражения, а также обоснованность проведения вакцинации. В статье представлены промежуточные результаты исследования «ОТКЛИК», посвященного оценке состояния иммунитета на протяжении до 90 сут после перенесенной COVID-19 легкого и бессимптомного течения. </p> <p><bold>Цель исследования</bold> — изучить динамику формирования нейтрализующих антител к спайковому (S) белку SARS-CoV-2 и особенности гуморального иммунитета у лиц, перенесших COVID-19 в легкой или бессимптомной форме, в зависимости от гендерной принадлежности и возраста. </p> <p><bold>Методы.</bold> Совместное научное исследование Военно-медицинской академии им. С.М. Кирова и Лабораторной службы «Хеликс» проводилось в период с 01.06.2020 по 01.08.2021 на базе диагностических центров «Хеликс» и представляло собой проспективное когорное нерандомизированное исследование. В исследование включены на текущий момент 1109 лиц мужского и женского пола в возрасте от 18 до 70 лет (средний возраст 38,2 года), получавших амбулаторное лечение по поводу легкой или бессимптомной формы заболевания. Всем включенным в исследование пациентам проводилось определение количественного содержания нейтрализующих антител класса IgG к S-белку возбудителя SARS-CoV-2 в венозной крови на 30-е, 45-е, 60-е, 90-е сут от последнего результата положительной полимеразной цепной реакции с обратной транскрипцией (ОТ-ПЦР) на нуклеиновую кислоту SARS-CoV-2 в биологическом материале, определяемых методом иммунохемилюминесцентного анализа (LIAISON XL, DiaSorin S.p.A., Италия).<bold> </bold></p> <p><bold>Результаты.</bold> Через 30 сут лишь у 0,9% молодых женщин (18–44 лет) и 0,8% мужчин той же возрастной категории после перенесенной инфекции антитела класса IgG к S-белку возбудителя SARS-CoV-2 не определялись. В других возрастных группах антитела определялись у всех участников исследования. Титр IgG постепенно нарастает до пиковой концентрации через 45 сут с сохранением этого уровня к 60 сут с последующей тенденцией к снижению через 90 сут от начала заболевания.<bold> </bold></p> <p><bold>Заключение</bold>.<bold> </bold>Полученные данные характеризуют сроки формирования и продолжительность гуморального ответа у пациентов, перенесших COVID-19 в легкой или бессимптомной форме. На 45-е сут антитела определялись у всех участников исследования, что свидетельствует об обязательном формировании постинфекционного гуморального иммунитета, который при легком или бессимптомном течении COVID-19 сохранялся у пациентов в течение как минимум 3 мес.</p></trans-abstract><kwd-group xml:lang="en"><kwd>SARS-COV-2</kwd><kwd>IgG</kwd><kwd>the immunity</kwd><kwd>the antibodies</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>SARS-COV-2</kwd><kwd>IgG</kwd><kwd>иммунитет</kwd><kwd>антитела</kwd><kwd>COVID-19</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed: 10.07.2020).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: https://doi.org/10.1038/s41586-020-2012-7</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kang HYJ, Wang YS, Tong ZH. Personal knowledge on novel coronavirus pneumonia. Chin Med J (Engl). 2020;(133):1121–1122. doi: https://doi.org/10.1097/cm9.0000000000000757</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Coronavirus Disease (COVID-19) Situation Reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed: 10.07.2020).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sfera A, Osorio C, Jafri N, et al. Intoxication with Endogenous Angiotensin II: A COVID-19 Hypothesis. Front Immunol. 2020;11:1472. doi: https://doi.org/10.3389/fimmu.2020.01472</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Салухов В.В., Гуляев Н.И., Дорохина Е.В. Оценка системных воспалительных реакций и коагулопатии на фоне гормональной терапии при ковид-ассоциированном поражении легких // Медицинский совет. — 2020. — № 21. — С. 230–237. [Salukhov VV, Gulyaev NI, Dorokhina EV. Assessment of systemic inflammatory reactions and coagulopathy against the background of hormonal therapy in covid-associated lung damage. Meditsinskiy sovet = Medical Council. 2020;(21):230–237. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2020-21-230-237</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Yong G, Yi Y, Tuantuan L, et al. Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2). J Med Virol. 2020;92(10):1975–1979. doi: https://doi.org/10.1002/jmv.25919</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020;92(10):2004–2010. doi: https://doi.org/10.1002/jmv.25930</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020;5 (18):e142386. doi: https://doi.org/10.1172/jci.insight.142386</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi: https://doi.org/10.1101/2020.09.06.20189480</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791–797. doi: https://doi.org/10.1099/jgv.0.001439</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kirkcaldy RD, King BA, Brooks JT. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions. JAMA. 2020;323(22):2245–2246. doi: https://doi.org/10.1001/jama.2020.7869</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Салухов В.В., Харитонов М.А., Крюков Е.В., и др. Актуальные вопросы диагностики, обследования и лечения больных с COVID-19-ассоциированной пневмонией в различных странах и континентах // Медицинский совет. — 2020. — № 21. — С. 96–102. [Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Meditsinskiy sovet = Medical Council. 2020;(21):96–102. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2020-21-96-102</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Зайцев А.А., Голухова Е.З., Мамалыга М.Л., и др. Эффективность пульс-терапии метилпреднизолоном у пациентов с СOVID-19 // Клиническая микробиология и антимикробная химиотерапия. — 2020. — Т. 22. — № 2. — С. 88–89. [Zaitsev AA, Golukhova EZ, Mamalyga ML, et al. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):88–89. (In Russ.)]</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Чугунов А.А., Салухов В.В., Данцева О.В., и др. Некоторые аспекты применения глюкокортикоидных препаратов в комплексном лечении новой коронавирусной инфекции // Медицинский альянс. — 2021. — Т. 9. — № 1. — С. 43–51. [Chugunov АA, Salukhov VV, Dantseva ОV, Kharitonov МA, et al. Some aspects of application glucocorticoid drugs in the complex treatment of new coronaviral infection. Medical Alliance. 2021;9(1):43–51. (In Russ.)] doi: https://doi.org/10.36422/23076348-2021-9-1-43-51</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734. doi: https://doi.org/10.1056/nejmoa2006100</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–442. doi: https://doi.org/10.1038/s41586-020-2456-9</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lau CS, Oh HML, Hoo SP, et al. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020;510:760–766. doi: https://doi.org/10.1016/j.cca.2020.09.005</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>World report on ageing and health. World Health Organization, Geneva, Switzerland;2015. 246 p. Available from: https://apps.who.int/iris/handle/10665/186463</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Bag Soytas R, Cengiz M, Islamoglu MS, et al. Does the COVID-19 seroconversion in older adults resemble the young? J Med Virol. 2021;93(10):5777–5782. doi: https://doi.org/10.1002/jmv.27106</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577–599. doi: https://doi.org/10.1146/annurev-cellbio-100616-060718</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi: https://doi.org/10.1038/nri.2016.90</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fink AL, Engle K, Ursin RL, et al. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci USA. 2018;115(49):12477–12482. doi: https://doi.org/10.1073/pnas.1805268115</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci USA. 2014;111(2):869–874. doi: https://doi.org/10.1073/pnas.1321060111</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–1163. doi: https://doi.org/10.1056/NEJMc070348</mixed-citation></ref></ref-list></back></article>
